Table 1.

Clinical characteristics of patients

Variables
Age, year
median	51
range	38–73
CA125, U/ml
median	1070
range	72.5–6546
Ascites, N (%)
No	8(33.33)
< 500 ml	14(58.33)
≥ 500 ml	2(8.33)
RD, N (%)
R0	14(58.33)
R1	5(20.83)
R2	5(20.83)
Treatment, N (%)
IDS	21(87.50)
PDS	2(8.33)
-	1(4.17)
NLNM size, N (%)
≤ 2 cm	17(70.83)
> 2 cm	7(29.17)
NLN evaluation after neoadjuvant chemotherapy, N (%)
SD	1(4.17)
CR	8(33.33)
PR	15(62.50)
BRAC gene testing, N (%)
BRCA mutant	59(20.83)
BRCA wild-type/BRCA status unknown	19(79.17)
Sites of first recurrence, N (%)
lymph nodes	4(26.67)
Abdomen or other distant sites(lung,brain,bone,…)	11(73.33)
Maintenance therapy, N (%)
Not obtain PARPi maintenance therapy	18(75)
Obtain PARPi maintenance therapy	6(25)

RD residual disease, R0 complete intra-abdominal tumor resection, R1 residual tumor > 0 and ≤ 1 cm, R2 residual tumor > 1 cm, IDS interval debulking surgery, PDS primary debulking surgery, CR complete response, PR partial response, SD stable disease